Oslo, Norway, 10 May 2023 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The company has recently filed three new patent applications enabling their proprietary technology to inhibit an even broader spectrum of bacterial enzymes that cause antibiotics resistance. This will give pipeline products a more attractive position in the marked and significantly extend marked exclusivity.
Bacteria produce several types of enzymes to combat antibiotics. Adjutec core technology is targeting an enzyme “family” that destroys last-resort antibiotics, increasingly resulting in morbidity and death of patients. As antibiotic resistance spread, each bacteria become clever and produce several types of enzymes. This is challenging to the clinician and requires antibiotics combined with broad-spectrum enzyme inhibitors. The new patents give Adjutec access to such products, which extend patent protection and increase investor and partner attractiveness.
At the world’s largest conference in infection medicine, ECCMID in Copenhagen, Adjutec received significant attention at posters and oral presentations. The latest scientific and market updates strongly supported the need for novel antibiotic products including enzyme inhibitor technologies.
Adjutec is raising capital for the phase 1 program and Bjørn Klem will attend the BioEquity meeting 13-14 May in Dublin. Having completed preclinical development to support the application of starting phase 1, the company wants to increase visibility towards potential R&D and commercial partners. Both Bjørn Klem and Professor Pål Rongved will attend US Bio 5-8 June in Boston this year.
“Securing and expanding market exclusivity of our products is essential for investors. The new patents will strengthen the positioning of our phase 1 ready product APC148 and support other pipeline products. We see great potential for our products in a medical environment that is looking for novel technologies to overcome antibiotic resistance”, comments CEO Bjørn Klem.
Full PR available here